MedTrace Logo

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

NCT05684016 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2023-01-13

No results posted yet for this study

Summary

The purpose of the research study is to investigate whether the extent and severity of lesions in the brain as measured by special MRI techniques can distinguish between Multiple Sclerosis (MS) patients with or without memory impairment and also between MS patients and age matched healthy controls.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

OTHER

NeuroQuant

Reliably defines the volume of those parts of the brain that are important for memory and thinking.

OTHER

Automated Neuropsychological Assessment Matrices

This is like an IQ test.

OTHER

EDSS

Extended Disability Status Score

OTHER

Physical Examination

Physical Examination

Sponsors & Collaborators

  • George Washington University

    lead OTHER

Principal Investigators

  • Ted Rothstein, MD · The George Washington University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-09-30
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05684016 on ClinicalTrials.gov